
Actavis
About Actavis
Actavis is a Healthcare company based in Parsippany Troy Hills (United States) founded in 1956, and was acquired by Teva Pharmaceuticals in July 2015. Manufacturer of generic products. Actavis has completed 7 acquisitions, including Allergan, Auden Mckenzie and Durata Therapeutics. Its Indian entity Actavis Pharma Development Centre Private Limited reported revenue of βΉ70.97 Cr. Its focus areas include Traditional Pharmaceuticals, Generics and Therapeutic Areas.
Company details
Actavis was founded in 1956 and is headquartered in Parsippany Troy Hills, United States. Operations focus on the pharmaceutical sector, with emphasis on generic drug production and distribution. The company acquired Allergan, leading to a name change to Allergan plc, though the U.S. and Canadian generics business continues under the Actavis brand. In 2013, annual revenues reached 5.91 billion, alongside a net profit of 0.09 billion.
- Headquarters Parsippany Troy Hills, United States
- Stage Acquired
- SectorsHealthcare
- Website actavis.com
- Social LinkedIn X
- Acquired by Teva Pharmaceuticals (Jul 2015)
- Legal Name Actavis Pharma Development Centre Private Limited
- Date of Incorporation 23 Aug, 2006
- Indian entity revenue₹70.97 Cr
FY 2026 · +1% YoY
- Indian entity net profit₹7.13 Cr
FY 2026 · 10% margin
- Indian entity EBITDA₹16.26 Cr
FY 2026 · 24% margin
- Investors
- Investments & AcquisitionsAllergan
& 6 more
- Acquired byTeva Pharmaceuticals
(Jul 2015)
Associated legal entities of Actavis
Actavis operates through Actavis Pharma Development Centre Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Actavis Pharma Development Centre Private Limited CIN U24239MH2006PTC163981 | Active | 23 Aug 2006 | Mumbai, Maharashtra | ₹71.0 Cr | 160 | 5 | View details |
Funding Insights of Actavis
- Total Rounds 1
All 1 funding rounds of Actavis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2014 | Debt – Conventional | β | β | β |
1 investors in total: 1 institutional.
Investors in Actavis
Actavis has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Teva Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | tevapharm.com | Petah Tikva, Israel |
Investor details for Actavis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Actavis Pharma Development Centre Private Limited (Actavis)
Actavis Pharma Development Centre Private Limited is the primary company behind Actavis. The board of Actavis Pharma Development Centre Private Limited currently have 3 directors; the longest-serving is Sunilkumar Patloba Nagargoje, appointed in 2019. 18 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sunilkumar Patloba Nagargoje DIN 08623096 | Director | 27 Nov 2019 | 6 yrs 11 mo | Actavis Pharma Development Centre Private Limited |
| Vinod Narayan Shetty DIN 09257187 | Director | 25 Aug 2021 | 5 yrs 2 mo | Actavis Pharma Development Centre Private Limited |
| Nishank Bhargava DIN 09472446 | Director | 23 Feb 2022 | 4 yrs 8 mo | Actavis Pharma Development Centre Private Limited |
Financials of Actavis
Figures of Actavis Pharma Development Centre Private Limited, the primary company behind Actavis, for FY 2026. Revenue was ₹70.97 Cr (+1% year on year). Net profit was ₹7.13 Cr (10% margin). EBITDA was ₹16.26 Cr (24% margin). Revenue has grown at a compounded annual rate of +15% over three years and +14% over five years.
- ₹70.97 CrRevenue · FY 2026 · +1% YoY
- ₹7.13 CrNet profit · 10% margin
- ₹16.26 CrEBITDA · 24% margin
- ₹13.02 CrPaid-up capital
- 160Employees (provident fund records)
- +15%Revenue CAGR, 3 years
- +14%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Actavis Pharma Development Centre Private Limited are on its company page.
Detailed financial statements for Actavis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Actavis
Actavis has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include Allergan, Auden Mckenzie and Durata Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of generic medicines | audenmckenzie.com | Castleford, United Kingdom | 2001 | Jan 2015 | $467.68M | |
A portfolio of generic medicines is developed and manufactured. | allergan.com | Madison, United States | 1948 | Nov 2014 | $70.5B | |
Novel antibiotics for infectious diseases are developed by the company. | duratatherapeutics.com | Chicago, United States | 2009 | Oct 2014 | β’β’β’β’ | |
Drug development for gastroenterology disorders is conducted. | furiex.com | Morrisville, United States | 2009 | Apr 2014 | $1.1B | |
Anti-allergic, metabolism, and other medical drugs are manufactured. | silommedical.co.th | Phaya Thai, Thailand | 1946 | Apr 2014 | $100M | |
Pharmaceutical formulations are developed and marketed by Forest Laboratories. | frx.com | New York, United States | 1954 | Feb 2014 | β’β’β’β’ | |
Contract research, development, and manufacturing for biologic drugs are offered. | wcrx.com | Rockaway, United States | 1999 | May 2013 | $8.5B |
Complete acquisition details for Actavis
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Actavis
11 dated milestones of Actavis across 59 years, from founding to its latest funding, stage changes and deals.
- Founded Actavis is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Warner Chilcott.
- Acquisition Acquires Forest Laboratories.
- Acquisition Acquires Silom Medical.
- Acquisition Acquires Furiex.
- Funding First funding round.
- Acquisition Acquires Durata Therapeutics.
- Acquisition Acquires Allergan.
- Acquisition Acquires Auden Mckenzie.
- Exit Acquired by Teva Pharmaceuticals.
Web traffic of Actavis
Websites that share an audience with Actavis (actavis.com).
Websites whose visitors overlap most with Actavis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
watson.com | watson.com | 100% | #14,435,464 | β | |
| pfizer.com | 91% | 1.9M | #24,984 | View details | |
abcfarmaceutici.it | abcfarmaceutici.it | 82% | #4,766,099 | β | |
baxteritalia.it | baxteritalia.it | 82% | #3,157,074 | β | |
| mylan.com | 78% | 26.4K | #1,585,141 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 16 similar websites and full traffic analytics for Actavis
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Actavis (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | USD 3.02 B | 8,300 | ||
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | USD 5.1 B | 13,500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Actavis
Complete news archive for Actavis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Actavis
Actavis was founded in 1956 and raised its 1st funding round 58 years after it was founded.
Actavis is headquartered in Parsippany Troy Hills, United States. It is registered at Parsippany Troy Hills, New Jersey, United States.
The primary company behind Actavis, Actavis Pharma Development Centre Private Limited, reported revenue of βΉ70.97 Cr for FY 2026, up 1% year on year.
Actavis was founded in 1956 and is headquartered in Parsippany Troy Hills, United States. Operations focus on the pharmaceutical sector, with emphasis on generic drug production and distribution. The company acquired Allergan, leading to a name change to Allergan plc, though the U.S. and Canadian generics business continues under the Actavis brand. In 2013, annual revenues reached 5.91 billion, alongside a net profit of 0.09 billion.
Actavis has made 7 acquisitions, including Allergan, Auden Mckenzie, and Durata Therapeutics.
Actavis has 1 investor. Key investors include Teva Pharmaceuticals.
Actavis operates through Actavis Pharma Development Centre Private Limited.
Yes. Actavis was acquired by Teva Pharmaceuticals in July 2015.
The legal entities of Actavis currently have 5 directors, including Sunilkumar Patloba Nagargoje, Shweta, Nishank Bhargava and others.
